The diagnosis and treatment of neurological ailments always remain an utmost challenge for
research fraternity due to the presence of BBB. The intranasal route appeared as an …

Breakthrough pain (BTP) is a transient exacerbation of pain that occurs either
spontaneously, or in relation to a specific predictable or unpredictable trigger, despite …

Breakthrough cancer pain (BTcP) is an episode of severe pain that “breaks through” a
period of persistent pain at least partly controlled by a stable opioid regimen. Although …

CONTEXT: We recently reported that fentanyl pectin nasal spray (FPNS) provides superior
pain relief from breakthrough cancer pain (BTCP) compared with immediate-release …

Breakthrough pain (BTP) is a transitory pain (reaching maximum severity in∼ 15 minutes
and lasting∼ 60 minutes in patients with cancer) that occurs despite the management of …

BACKGROUND: Immediate-release morphine sulfate (IRMS) remains the standard
treatment for breakthrough cancer pain (BTCP), but its onset of effect does not match the …

Objective A major goal of palliative care is to provide comfort, and pain is one of the most
common causes of treatable suffering in patients with advanced disease. Opioids are …

Context Episodic breathlessness is common and debilitating in cancer patients. Objectives
In this pilot study, we examined the effect of prophylactic fentanyl pectin nasal spray (FPNS) …

Clinical management of breakthrough cancer pain (BTcP) is still not satisfactory despite the
availability of effective pharmacological agents. This is in part linked to the lack of clarity …

Many of the increasing number of intranasal products available for either local or systemic
action can be considered sub-optimal, most notably where nasal drip or run-off give rise to …